• F Javier Ampudia-Blasco, Ana Palanca, Jose Luis Trillo, Jorge Navarro, and Jose T Real.
• Department of Endocrinology & Nutrition, Clinic University Hospital and INCLIVA, Valencia, Spain; Department of Medicine, Medicine Faculty, University of Valencia (UV), Valencia, Spain; CIBERDEM, CIBER de Diabetes y Enfermedades Metabólicas asociadas, Madrid, Spain.
• J. Diabetes Complicat. 2021 Mar 1; 35 (3): 107828.

AimsTo analyze therapeutic inertia in type 2 diabetes (T2D) subjects with suboptimal glycemic control and treated with ≥2 non-insulin antidiabetic agents in a primary care setting.MethodsA retrospective study was conducted using electronic medical records from subjects with HbA1c ≥7.0% (≥53 mmol/mol). Therapeutic inertia was defined as the absence of treatment intensification despite suboptimal glycemic control where intensification should have been implemented (HbA1c ≥7.5% [≥58 mmol/mol]). Time to the first intensification with non-insulin antidiabetic agent or insulin and HbA1c values at the time of intensification were evaluated by competing risk analysis.Results2652 adults with T2D and HbA1c ≥7.0% (≥53 mmol/mol) were included. During the 4-year follow-up, among 1628 individuals with HbA1c ≥7.5% [≥58 mmol/mol], therapeutic inertia was present in 42.9% of cases. Median time to intensification was 14.5 months (IQR25-75, 4-24 months). In this subgroup, 72.7% of subjects initiated non-insulin agents whereas 27.3% initiated insulin. Mean HbA1c values at initiation of treatment intensification were 8.6% (70 mmol/mol) and 9.2% (77 mmol/mol), respectively.ConclusionsTherapeutic inertia occurred in over 40% of subjects. Treatment intensification took longer and was performed at higher HbA1c than recommended in clinical guidelines. Reducing therapeutic inertia is a priority to achieve therapeutic goals and prevent chronic complications in T2D.Copyright © 2020 Elsevier Inc. All rights reserved.

5 keywords...

hide…